Literature DB >> 22526481

Risk of malignancy in follicular thyroid neoplasm: predictive value of thyrotropin.

M Zimny1, I Selkinski, S Blasius, T Rink, H-J Schroth, F Grünwald.   

Abstract

UNLABELLED: The cytological diagnosis of follicular neoplasm is a common finding in fine needle aspiration cytology (FNAC) of thyroid nodules and includes benign disease as well as differentiated thyroid cancer. The aim of the study is to determine if thyrotropin is a predictive factor for a malignant nature of follicular neoplasm. PATIENTS,
METHODS: The records of 119 patients with follicular neoplasm on FNAC, who underwent surgery for final diagnosis, were reviewed retrospectively. The predictive value of serum parameters including thyrotropin, thyroglobulin, and anti-thyroid antibodies, ultrasonographic criteria and clinical variables was evaluated by univariate analysis and logistic regression analysis. RESULTS, DISCUSSION: Patients with malignant nodules showed a higher thyrotropin concentration compared to patients with benign nodules (median 1.6 mU/l, interquartile range 1.4-3.0 mU/l vs. median 1.2 mU/l, interquartile range 0.8-1.6 mU/l, p < 0.01). ROC-analysis of thyrotropin revealed an optimal cut off value to differentiate benign and malignant nodules of 1.34 mU/l. The incidence of malignancy was 30.3% for a thyrotropin concentration higher than 1.34 mU/l compared to 6.4% for a thyrotropin concentration lower than or equal to 1.34 mU/l. On univariate analysis thyroglobulin higher than 300 ng/ml, positive anti-thyroid antibodies, hypoechogenicity, and ill-defined margins, respectively, were also significantly associated with malignancy. On logistic regression analysis higher thyrotropin concentrations, ill-defined margins, and thyroglobulin higher than 300 ng/ml, respectively, were independent predictive factors for malignancy (OR 20.0, 10.7, and 22.7, respectively).
CONCLUSION: Higher thyrotropin concentrations are predictive for a malignant nature of follicular neoplasm.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22526481     DOI: 10.3413/Nukmed-0456-12-01

Source DB:  PubMed          Journal:  Nuklearmedizin        ISSN: 0029-5566            Impact factor:   1.379


  2 in total

1.  Thyroid-Stimulating Hormone, Thyroid Hormones, and Risk of Papillary Thyroid Cancer: A Nested Case-Control Study.

Authors:  Huang Huang; Jennifer Rusiecki; Nan Zhao; Yingtai Chen; Shuangge Ma; Herbert Yu; Mary H Ward; Robert Udelsman; Yawei Zhang
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-04-04       Impact factor: 4.254

2.  Incidental thyroid carcinoma diagnosed after total thyroidectomy for benign thyroid diseases: incidence and association with thyroid disease type and laboratory markers.

Authors:  D Askitis; E I Efremidou; M Karanikas; A Mitrakas; G Tripsianis; A Polychronidis; N Liratzopoulos
Journal:  Int J Endocrinol       Date:  2013-11-20       Impact factor: 3.257

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.